Document Detail


Importance of 123I-metaiodobenzylguanidine scintigraphy/single photon emission computed tomography for diagnosis and differential diagnostics of Parkinson syndromes.
MedLine Citation:
PMID:  20616568     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The goal of Parkinson syndrome diagnostics is twofold: early diagnosis on the one hand, and accurate differentiation among idiopathic and atypical Parkinson syndromes on the other. (123)I-metaiodobenzylguanidine scintigraphy is the only method that can distinguish with a high degree of sensitivity and specificity between atypical Parkinson syndromes and Parkinson's disease or dementia with Lewy bodies. Additional advantages are the method's widespread availability and radioactive exposure dose comparable to that for single photon emission computed tomography imaging with much lower costs. Only a single radiotracer study is necessary. (123)I-metaiodobenzylguanidine scintigraphy is an indispensable tool for purposes of differentiating among the various Parkinson syndromes.
Authors:
Wolfgang H Jost; Kelly Del Tredici; Christian Landvogt; Stefan Braune
Related Documents :
19483488 - Oxcarbazepine treatment of restless legs syndrome: three case reports.
11110438 - Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic exp...
7551318 - Regular wide qrs complex tachycardia during atrial fibrillation in a patient with preex...
3683048 - Toxic shock syndrome in nasal surgery: a physiochemical and microbiologic evaluation of...
8723108 - Rectal atresia as rare manifestation in eec syndrome.
8435798 - Crystalglobulinemia syndrome. a manifestation of multiple myeloma.
Publication Detail:
Type:  Journal Article     Date:  2010-07-12
Journal Detail:
Title:  Neuro-degenerative diseases     Volume:  7     ISSN:  1660-2862     ISO Abbreviation:  Neurodegener Dis     Publication Date:  2010  
Date Detail:
Created Date:  2010-07-29     Completed Date:  2010-11-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101189034     Medline TA:  Neurodegener Dis     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  341-7     Citation Subset:  IM    
Copyright Information:
Copyright 2010 S. Karger AG, Basel.
Affiliation:
Department of Neurology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany. jost.neuro@dkd-wiesbaden.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
3-Iodobenzylguanidine / diagnostic use*
Antithyroid Agents / diagnostic use
Brain / pathology
Diagnosis, Differential
Early Diagnosis
False Negative Reactions
False Positive Reactions
Humans
Image Interpretation, Computer-Assisted
Movement Disorders / diagnosis,  radionuclide imaging
Parkinson Disease / diagnosis*,  pathology,  radionuclide imaging*
Radiopharmaceuticals / diagnostic use*
Tomography, Emission-Computed, Single-Photon / methods*
Chemical
Reg. No./Substance:
0/Antithyroid Agents; 0/Radiopharmaceuticals; 77679-27-7/3-Iodobenzylguanidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Positron Emission Tomography in Diagnosis and Differential Diagnosis of Parkinson's Disease.
Next Document:  Characterisation of the expression of the Renin-Angiotensin system in primary and immortalised human...